Recent results provided “reassuring” early evidence that taking noninsulin antidiabetic medications (ADMs) for type 2 diabetes—including glucagon-like peptide 1 (GLP-1) receptor agonists—during early pregnancy is not linked with a greater risk of major birth defects than taking insulin. The researchers followed up the children of more than 50 000 pregnant people in 6 countries for 1 year after they were born, monitoring them for conditions such as cleft palate and congenital hydrocephalus.
